TESARO is an oncology-focused biopharmaceutical company.
TESARO is dedicated to improving the lives of cancer patients by developing and providing safer and more effective therapeutics and supportive care products.
Contact
TESARO Bio GmbH.
Poststrasse 6
6300 ZUG
Switzerland
| www.tesarobio.com
|
The Chief Scientific Officer and President of Glenmark Pharmaceuticals Swiss R&D Center elaborates on Glenmark’s endeavor to venture up the pharmaceutical value chain and discusses the company’s R&D strategy. Furthermore,…
In the marketing-driven dermocosmetics sector, the Swiss cosmetics association has recently achieved the passage of a strict new law limiting the usage of the “made in Switzerland” claim for cosmetics…
Despite increasing consolidation in the clinical trial industry, there’s enough market share to go around says SOCAR Research CEO Bridget-Anne Kirwan. For SOCAR Research, it’s the company’s strong academic roots…
With more than 20 years of experience working with the Swiss pharmaceutical sector, general manager Roland Laudenbacher explains that Honeywell Building Solutions has developed a true specialization in projects for…
The managing director of Stallergenes Greer Switzerland, Claude Fischlewitz, explains how he has gone about revitalizing the company’s presence in Switzerland, while expressing his ambitions to restore and firmly position…
As Artificial Intelligence and Next Generation Sequencing started to converge, Sophia Genetics was created to bring the world towards an era of real-time epidemiology. CEO Jurgi Camblong discusses the company’s…
Strongly positioned in automated materiel and medication management, Swisslog Healthcare’s CEO Stephan Sonderegger is working to leverage the company’s physical infrastructure to collect data and become a leading player in…
Alpex Pharma is a specialized manufacturer of niche oral delivery forms, both for third parties and for their own portfolio of products for out-licensing. Managing Director Shahbaz Ardalan discusses the…
The General Manager of bioMérieux Switzerland and Austria highlights the significance of Switzerland for the company’s regional cluster and furthermore explains how Switzerland contributes to the global development of the…
With a recent clinical trial showing one of Bioforce’s Echinacea products to be non-inferior to the gold standard allopathic treatment Tamiflu, CEO Peter Gmünder is working to continue the work…
EY’s Biotech Team Leader for the EMEIA region discusses the challenges Europe’s fragmented capital markets pose for biotech startups, the under-communicated benefits of doing an IPO on the Swiss stock…
“Robust solutions, the capability to implement them and the ability to do so globally” – The executive president of product and brand protection solutions at SICPA explains why the company…
See our Cookie Privacy Policy Here
